HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 TRANSLOCATIONS
Clinical trials for HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 TRANSLOCATIONS explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 TRANSLOCATIONS trials appear
Sign up with your email to follow new studies for HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 TRANSLOCATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot shows promise against tough lymphoma in major trial
Disease control OngoingThis phase 3 trial compares a new immunotherapy called epcoritamab (given as a shot under the skin) to standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 483 participants will be randomly assigned to re…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 TRANSLOCATIONS
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New shot shows promise for tough lymphoma cases
Disease control OngoingThis study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 participants in China will be randomly assigned to get eithe…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 TRANSLOCATIONS
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for aggressive lymphoma: targeted combo shows promise in early trial
Disease control OngoingThis study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 TRANSLOCATIONS
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC